輝瑞預計今年新冠口服藥收入腰斬
格隆匯2月1日丨輝瑞昨日公佈2022年財報,期內營收同比增23%,達1003億美元,創歷史新高;淨利潤同比增長43%,達313.72億美元。輝瑞表示,2023年營收預期下降,完全是因為新冠產品的預期收入將會下滑。該公司稱,由於政府手頭有大量的新冠產品庫存,預計新冠產品的收入將在2023年進入低谷,不過這部分收入將在2024年實現反彈。財報顯示,新冠疫苗Comirnaty的2023年營收指引為135億美元,較2022年的實際收入下降64%;新冠口服藥Paxlovid約為80億美元,較2022年的實際收入下降58%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.